Document is current
Any future updates will be listed below
-
Authors
Nissani, Abraham
Lev-Ari, Shaked
Meirson, Tomer
Jacoby, Elad
Asher, Nethanel https://orcid.org/0000-0002-4094-8045
Ben-Betzalel, Guy
Itzhaki, Orit
Shapira-Frommer, Ronnie
Schachter, Jacob
Markel, Gal
Besser, Michal J. https://orcid.org/0000-0002-9233-0458
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00287131 at ClinicalTrials.govnct03166397 at ClinicalTrials.govDocuments that mention this clinical trial
TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction
https://doi.org/10.1136/jitc-2024-010145
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
https://doi.org/10.1136/jitc-2020-001743
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
https://doi.org/10.1136/jitc-2019-000148
nct03166397 at ClinicalTrials.govDocuments that mention this clinical trial
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
https://doi.org/10.1136/jitc-2020-001743
nct02772198 at ClinicalTrials.govDocuments that mention this clinical trial
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
https://doi.org/10.1136/jitc-2020-001743
nct00287131 at ClinicalTrials.govDocuments that mention this clinical trial
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
https://doi.org/10.1136/jitc-2020-001743
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
https://doi.org/10.1136/jitc-2019-000148
nct03166397 at ClinicalTrials.govDocuments that mention this clinical trial
TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction
https://doi.org/10.1136/jitc-2024-010145
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
https://doi.org/10.1136/jitc-2020-001743
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
https://doi.org/10.1136/jitc-2019-000148
nct02772198 at ClinicalTrials.govDocuments that mention this clinical trial
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
https://doi.org/10.1136/jitc-2020-001743
Documents that mention this clinical trial
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
https://doi.org/10.1136/jitc-2020-001743
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
https://doi.org/10.1136/jitc-2019-000148
- License Information
